Andrea Piunti

Andrea Piunti

Auto-generated profile, based on publicly available information

Andrea Piunti

Simpson Querrey Center for Epigenetics, Northwestern University Feinberg School of Medicine, 320 East Superior Street, Chicago, IL 60611, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2018 in Science Advances
Verified
Journal Article
Open access
PDF file
LWLu Wang
Lu Wang
POPatrick A. Ozark
Patrick A. Ozark
ESEdwin R. Smith
Edwin R. Smith
ZZZibo Zhao
Zibo Zhao
SMStacy A. Marshall
Stacy A. Marshall
ASAli Shilatifard
Ali Shilatifard
An epigenetic axis directs a transcriptional program via enhancer activation by MLL3 COMPASS and TET2-dependent DNA demethylation.

5 July 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
APAndrea Piunti
Andrea Piunti
ESEdwin R. Smith
Edwin R. Smith
MMMarc A. J. Morgan
Marc A. J. Morgan
MUMichal Ugarenko
Michal Ugarenko
NKNatalia Khaltyan
Natalia Khaltyan
ASAli Shilatifard
Ali Shilatifard
CATACOMB is a catalytic antagonist PRC2 subunit whose expression is induced upon DNA demethylation.

7 October 2022 in Science Advances
Verified
Journal Article
Open access
APAndrea Piunti
Andrea Piunti
KMKhyati Meghani
Khyati Meghani
YYYanni Yu
Yanni Yu
ARA. Gordon Robertson
A. Gordon Robertson
JPJoseph R. Podojil
Joseph R. Podojil
JMJoshua J. Meeks
Joshua J. Meeks
The long-term survival of patients with advanced urothelial carcinoma (UCa) is limited because of innate resistance to treatment. We identified elevated expression of the histone methyltransferase EZH2 as a hallmark of aggressive UCa and hypothesized that EZH2 inhibition, via a small-molecule catalytic inhibitor, might have antitumor effects in UCa. Here, in a carcinogen-induced mouse bladder cancer model, a reduction in tumor progression and an increase in immune infiltration upon EZH2 inhibition were observed. Treatment of mice with EZH2i causes an increase in MHC class II expression in the urothelium and can activate infiltrating T cells. Unexpectedly, we found that the lack of an intact adaptive immune system completely abolishes the antitumor effects induced by EZH2 catalytic inhibition. These findings show that immune evasion is the only important determinant for the efficacy of EZH2 catalytic inhibition treatment in a UCa model.

7 October 2016 in Science Advances
Verified
Journal Article
Open access
PDF file
ARAlessandra Rossi
Alessandra Rossi
KFKarin J. Ferrari
Karin J. Ferrari
APAndrea Piunti
Andrea Piunti
SJSriGanesh Jammula
SriGanesh Jammula
FCFulvio Chiacchiera
Fulvio Chiacchiera
DPDiego Pasini
Diego Pasini
Leukemia is a complex heterogeneous disease often driven by the expression of oncogenic fusion proteins with different molecular and biochemical properties. Whereas several fusion proteins induce leukemogenesis by activating Hox gene expression (Hox-activating fusions), others impinge on different pathways that do not involve the activation of Hox genes (non–Hox-activating fusions). It has been postulated that one of the main oncogenic properties of the HOXA9 transcription factor is its ability to control the expression of the p16/p19 tumor suppressor locus (Cdkn2a), thereby compensating Polycomb-mediated repression, which is dispensable for leukemias induced by Hox-activating fusions. We show, by genetically depleting the H2A ubiquitin ligase subunits of the Polycomb repressive complex 1 (PRC1), Ring1a and Ring1b, that Hoxa9 activation cannot repress Cdkn2a expression in the absence of PRC1 and its dependent deposition of H2AK119 monoubiquitination (H2AK119Ub). This demonstrates the essential role of PRC1 activity in supporting the oncogenic potential of Hox-activating fusion proteins. By combining genetic tools with genome-wide location and transcription analyses, we further show that PRC1 activity is required for the leukemogenic potential of both Hox-activating and non–Hox-activating fusions, thus preventing the differentiation of leukemic cells independently of the expression of the Cdkn2a locus. Overall, our results genetically demonstrate that PRC1 activity and the deposition of H2AK119Ub are critical factors that maintain the undifferentiated identity of cancer cells, positively sustaining the progression of different types of leukemia.

1 February 2024 in JCO Precision Oncology
Verified
Journal Article
Closed access
MCMohansrinivas Chennakesavalu
Mohansrinivas Chennakesavalu
KMKelley Moore
Kelley Moore
GCGepoliano Chaves
Gepoliano Chaves
SVSahil Veeravalli
Sahil Veeravalli
RTRachel TerHaar
Rachel TerHaar
MAMark Applebaum
Mark Applebaum
PURPOSE: Neuroblastoma is the most common extracranial solid tumor in childhood. We previously showed that circulating cell-free DNA (cfDNA) and tumor biopsy derived 5-hydroxymethylcytosime (5-hmC) profiles identified patients with neuroblastoma who experienced subsequent relapse. Here, we hypothesized that 5-hmC modifications selectively enriched in cfDNA compared with tumor biopsy samples would identify epigenetic changes associated with aggressive tumor behavior and identify novel biomarkers of outcome in patients with high-risk neuroblastoma. METHODS: 5-hmC profiles from cfDNA (n = 64) and tumor biopsies (n = 48) were compared. Two neuroblastoma cell lines underwent chromatin immunoprecipitation followed by sequencing (ChIP-Seq) for H3K27me3, H3K4me3, and H3K27ac; kethoxal-associated single-stranded DNA sequencing; hmC-Seal for 5-hmC; and RNA-sequencing (RNA-Seq). Genes enriched for both H3K27me3 and H3K4me3 in the included cell lines were defined as bivalent. Using bivalent genes defined in vitro, a bivalent signature was established in three publicly available cohorts of patients with neuroblastoma through gene set variation analysis. Differences between tumors with high or low bivalent signatures were assessed by the Kaplan-Meier method and Cox proportional hazards models. RESULTS: In cfDNA compared with tumor biopsy derived 5-hmC profiles, we found increased 5-hmC deposition on Polycomb Repressive Complex 2 target genes, a finding previously described in the context of bivalent genes. We identified 313 genes that bore bivalent chromatin marks, were enriched for mediators of neuronal differentiation, and were transcriptionally repressed across a panel of heterogeneous neuroblastoma cell lines. In three distinct clinical cohorts, low bivalent signature was significantly and independently associated with worse clinical outcome in patients with high-risk neuroblastoma. CONCLUSION: Low expression of bivalent genes is a biomarker of worse outcome in patients with high-risk neuroblastoma.

9 July 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
MCMohansrinivas Chennakesavalu
Mohansrinivas Chennakesavalu
GLGabriel L. Lopez
Gabriel L. Lopez
VGVarsha Gupta
Varsha Gupta
KMKelley Moore
Kelley Moore
YXYuqing Xue
Yuqing Xue
MAMark Applebaum
Mark Applebaum
MYCN -amplification is a strong predictor of poor prognosis in neuroblastoma, an embryonal malignancy that accounts for 15% of pediatric cancer deaths. Here, we found that MYCN -amplified neuroblastoma tumors had increased 5-hydroxymethylcytosine (5-hmC) deposition on Polycomb Repressive Complex 2 (PRC2) target genes. 5-hmC and H3K27me3, a catalytic product of PRC2, directly co-localized at the nucleosomal level in MYCN -amplified neuroblastoma. Genes with co-localization of 5-hmC/H3K27me3 were involved in development related pathways and were transcriptionally repressed in MYCN -amplified neuroblastoma. Inhibition of 5-hmC deposition resulted in a loss of H3K27me3 on protein-coding genes and sensitized neuroblastoma to DNA demethylating agents. 5-hmC deposition predisposed H3K27me3 marked genes to transcriptional activation upon PRC2 inhibition with tazemetostat. Low expression of genes marked by 5-hmC/H3K27me3 was associated with poor clinical outcome. Our results suggest that 5-hmC/H3K27me3 co-operate to repress mediators of development highlighting a novel link between DNA and chromatin modifications with potential therapeutic implications in MYCN -amplified neuroblastoma.